参莲胶囊联合奥希替尼对EGFR突变的晚期非小细胞肺癌（气阴两虚证）的疗效分析

Effect analysis of Shenlian Capsule combined with osimertinib on advanced EGFR mutated non-small cell lung cancer （qi and yin deficiency syndrome）

关键词:  参莲胶囊  奥希替尼  EGFR突变的晚期非小细胞肺癌  气阴两虚证  疗效

Key words:  Shenlian Capsule  osimertinib  advanced non-small cell lung cancer with EGFR mutation  qi and yin deficiency syndrome  curative effect

摘要:

[目的] 探讨参莲胶囊联合奥希替尼对EGFR突变的晚期非小细胞肺癌（气阴两虚证）的疗效分析。[方法] 选取2021年4月—2022年4月本院收治的表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌患者110例，按照随机数表法分2组，对照组（55例）给予奥希替尼，研究组（55例）在对照组基础上加用参莲胶囊。比较两组治疗效果、用药安全性、欧洲癌症研究和治疗组织肿瘤患者生存质量量表（EORTCQLQ-LC43）评分以及癌胚抗原（CEA），细胞角蛋白19片段（CYFRA21-1），糖类抗原125（CA125）。[结果] 研究组总有效率高于对照组（P<0.01）。治疗后，两组患者血清CEA，CA125，CYFRA21-1水平明显低于治疗前（P<0.01），研究组血清CEA，CA125和CYFRA21-1水平明显低于对照组（P<0.05）。研究组不良反应发生率低于对照组（P<0.05）。治疗后研究组和对照组患者角色功能、生理功能、认知功能、社会功能、情感功能、总健康状况评分均较治疗前明显增加（P<0.05），治疗后研究组角色功能、生理功能、认知功能、社会功能、情感功能、总健康状况评分高于对照组（P<0.05）。[结论] 参莲胶囊联合奥希替尼对EGFR突变的晚期非小细胞肺癌（气阴两虚证）的治疗效果较好，并具有安全性，还可以有效降低血清CEA，CA125和CYFRA21-1水平，提高患者生活质量，在临床上有着广阔的应用前景。

Abstract:

[Objective] To investigate the curative effect of Shenlian Capsule combined with osimertinib on advanced EGFR mutated non-small cell lung cancer（qi and yin deficiency syndrome）. [Methods] A total of 110 patients with advanced non-small cell lung cancer with EGFR mutation admitted to our hospital from April 2021 to April 2022 were randomly divided into two groups. The control group（55 cases） was given osimertinib，and the study group（55 cases） was given Shenlian Capsule on the basis of the control group. The therapeutic effect，drug safety，European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 43（EORTCQLQ-LC43） scores，carcinoembryonic antigen（CEA），cytokeratin 19 fragment（CYFRA21-1），carbohydrate antigen 125（CA125） were compared between the two groups. [Results] The total effective rate of the study group was higher than that of the control group（P<0.01）. After treatment，the levels of serum CEA，CA125 and CYFRA21-1 in the two groups were obviously lower than those before treatment（P<0.01），and the levels of serum CEA，CA125 and CYFRA21-1 in the study group were obviously lower than those in the control group（P<0.05）. The incidence of adverse reactions in the study group was lower than that in the control group（P<0.05）. After treatment，the role function，physiological function，cognitive function，social function，emotional function，and overall health status scores of patients in the study group and control group were significantly increased compared to before treatment（P<0.05）. After treatment，the role function，physiological function，cognitive function，social function，emotional function，and overall health status scores of the study group were higher than those of the control group（P<0.05）. [Conclusion] Shenlian Capsule combined with osimertinib is effective and safe in the treatment of advanced EGFR non-small cell lung cancer（qi and yin deficiency syndrome）. It can also effectively reduce the levels of serum CEA，CA125 and CYFRA21-1，improve the quality of life of patients. and has broad clinical application prospects.